Showing results (21-30 of 161) with videos related to
Sort By:
Pageof 17
The Journal of Physiology|September 7, 2022
Using the genome to correct the ion transport defect in cystic fibrosisMargarida D AmaralCurrent Opinion in Pharmacology|March 7, 2022
Precision medicine for rare diseases: The times they are A-Changin'Margarida D AmaralMolecular Diagnosis & Therapy|September 13, 2025
Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular ModelsVioleta Railean, Cláudia S Rodrigues, Ines Pankonien, et al.Trends in Pharmacological Sciences|June 19, 2007
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosisMargarida D Amaral, Karl KunzelmannCellular and Molecular Life Sciences : CMLS|April 22, 2020
A central role of the endoplasmic reticulum in the cell emerges from its functional contact sites with multiple organellesCelso Almeida, Margarida D AmaralBiochemical and Biophysical Research Communications|April 14, 2012
Ahnak1 interaction is affected by phosphorylation of Ser-296 on Cavβ₂Ines Pankonien, Albrecht Otto, Nathan Dascal, et al.Pharmaceutics|January 21, 2023
What Can RNA-Based Therapy Do for Monogenic Diseases?Luka A Clarke, Margarida D AmaralJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 1, 2022
Development of novel therapeutics for all individuals with CF (the future goes on)Margarida D Amaral, Patrick T HarrisonMolecular and Cellular Biology|June 1, 2005
Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexinCarlos M Farinha, Margarida D AmaralJournal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 22, 2019
Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutationsMargarida D Amaral, Kris de Boeck, Pageof 17